{"url_path":"/sec/biaf/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-031327-index.html","accession_number":"0001493152-26-031327","cik":"0001712762","ticker":"BIAF","issuer_name":"bioAffinity Technologies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-031327-index.html","primary_entity_key":"0001712762","primary_entity_name":"bioAffinity Technologies, Inc."},"word_count":96,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n99.1\n \n[Company Newsletter, 1st Edition, 2nd Quarter 2026, released by bioAffinity Technologies, Inc. on June 30, 2026](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the XBRL document)\n\n** **\n\n****\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K\nto be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 30, 2026\n**BIOAFFINITY\nTECHNOLOGIES, INC.**\n\n \n \n\n \nBy:\n*/s/\nMaria Zannes*\n\n \nName:\nMaria\nZannes\n\n \nTitle:\nPresident\nand Chief Executive Officer"}